Galena Biopharma (GALE)
Create an Alert
2.03
-0.05 -2.40%
NASDAQ
Jun 19, 1:19PM
BATS Real time
Currency in USD
Galena Biopharma Debt to Equity Ratio:
0.00 for Dec. 31, 2012Galena Biopharma Historical Debt to Equity Ratio Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2012 | 0.00 |
| Sept. 30, 2012 | 0.00 |
| June 30, 2012 | 0.00 |
| March 31, 2012 | |
| Dec. 31, 2011 | 0.0494 |
| Sept. 30, 2011 | 0.1062 |
| June 30, 2011 | 0.00 |
| March 31, 2011 | 0.00 |
| Dec. 31, 2010 | 0.00 |
| Sept. 30, 2010 | 0.00 |
| June 30, 2010 | 0.00 |
| March 31, 2010 | 0.00 |
| Dec. 31, 2009 | 0.00 |
| Sept. 30, 2009 | 0.00 |
| June 30, 2009 | 0.00 |
| March 31, 2009 | 0.00 |
| Dec. 31, 2008 | 0.00 |
| Sept. 30, 2008 | 0.00 |
| June 30, 2008 | 0.0012 |
About Debt to Equity Ratio
Leverage ratio indicating the relative proportion of shareholders' equity and debt used to finance a company's assets. A low debt to equity ratio indicates lower risk, because debt holders have less claims on the company's assets. A debt to equity ratio of 5 means that debt holders have a 5 times more claim on assets than equity holders.
A high debt to equity ratio usually means that a company has been aggressive in financing growth with debt and often results in volatile earnings.
It is also known as Debt/Equity Ratio, Debt-Equity Ratio, and D/E Ratio.
Learn More
GALE Debt to Equity Ratio Benchmarks
| Companies | |
|---|---|
| Celldex Therapeutics | 0.0516 |
| ImmunoCellular Therapeutics | 0.00 |
| Northwest Biotherapeutics |
GALE Debt to Equity Ratio Rankings
| Overall |
99th percentile 1 of 16782 |
| Sector |
99th percentile 1 of 1410 in Healthcare |
| Industry |
99th percentile 1 of 454 in Biotechnology |
GALE Debt to Equity Ratio Range, Past 5 Years
| Minimum | 0.000 | Sep 2008 |
| Maximum | 0.1062 | Sep 2011 |
| Average | 0.0087 |
